AbbVie announces results from Phase 2 IMGN853-0420 trial

AbbVie (ABBV) announced that late-breaking results from the Phase 2 IMGN853-0420 trial will be presented in an oral session at the 2026 Society of Gynecologic Oncology, SGO, Annual Meeting. The study evaluated the potential efficacy and safety of mirvetuximab soravtansine-gynx, Elahere, in combination with carboplatin followed by maintenance of mirvetuximab soravtansine-gynx monotherapy, in patients with folate receptor alpha-expressing, recurrent platinum-sensitive ovarian cancer, PSOC. The multicenter, open-label study enrolled 125 patients with FRalpha-positive, measurable disease who had received one prior platinum-based chemotherapy regimen. The primary endpoint of the study was a confirmed objective response rate in the greater than or equal to50% FRalpha subgroup after six cycles of combination therapy. Key secondary endpoint was ORR after six cycles in the overall population and additional secondary endpoints included duration of response, progression-free survival and overall survival.